Endocyte — Technical Presentation (December 2011)
17 slides from Endocyte's technical presentation, Dec 13, 2011
Slide 1: Supplemental PRECEDENT Trial Analysis
Endocyte Inc. Supplemental PRECEDENT Trial Analysis December 13, 2011 Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements During the course of this presentation, we will make forward-looking statements regarding future events and our future performance. The words “believe”, “anticipate”, “expect”, “estimate”, “intend”, “plan”, “may”, “will” and other similar expressions generally identify for
Slide 3: PRECEDENT Trial Supplemental Analysis
PRECEDENT Trial Supplemental Analysis Purpose Results Validate EC20 to select FR positive patients Validated (inter-reader agreement 85%) Test robustness of PFS primary endpoint (investigator assessed) PFS robust (no evidence of bias) Confirmed PFS results in FR(++) group Update OS analysis (102 eve
Slide 4: Platinum-Resistant Ovarian Cancer Is an Attractive Patient Population for Drug Approvals
Platinum resistant ovarian cancer patients (failed first or second platinum therapy < 6 months) EC145 + PLD PLD only FR Positive Platinum-Resistant Ovarian Cancer Is an Attractive Patient Population for Drug Approvals • Platinum-resistant ovarian cancer overall survival 12.7 months • Current drugs d
Slide 5: Validates EC20
EC20 Validates Reader Agreement FR(+) > 1 positive lesion 87% FR(++) all lesions positive 85% Independent reader study validates EC20 to select FR positive patients for phase 3 study Targeted >70% agreement
Slide 6: Investigator PFS Assessment Passed
Investigator PFS Assessment Passed Standard Battery of Tests for Robustness Test for Imbalances Pass / Fail Results Patient populations Pass Adjusted for imbalances in patient prognostic factors (e.g. performance status) HR 0.597* Study discontinuance Pass Treat discontinuance as event HR 0.610* Cli
Slide 7: As Expected Treatment Arm Median Decreased More Than Control Arm
As Expected Treatment Arm Median Decreased More Than Control Arm Note: of patients with > follow up CT scan – EC145/PLD and PLD
Slide 8: Investigator and IRC PFS Results
Investigator and IRC PFS Results FR(++) results are statistically significant and clinically meaningful in both analyses
Slide 9: PFS Conclusions
PFS Conclusions • Primary endpoint (investigator assessed PFS) is robust and unbiased • IRC confirmed statistically significant and clinically meaningful results in FR(++) group • Greater confidence that phase 2 results can be repeated in phase 3 (blinded) confirmatory study
Slide 10: Historical PLD Phase Trials in Platinum Resistant Ovarian Cancer
Historical PLD Phase 3 Trials in Platinum Resistant Ovarian Cancer Study Drug N OS Gordon et al. (2004) PLD 8.3 Topotecan 9.5 Mutch et al. (2007) PLD 13.5 Gemcitabine 12.7 Ferrandina et al. (2008) PLD 12.7 Gemcitabine 11.5 Vergote et al. (2009) PLD or Topotecan 13.5 Canfosfamide 8.5 Monk et al. (201
Slide 11: Overall Survival Underpowered and Indeterminate
Overall Survival Underpowered and Indeterminate Overall Survival ITT n=149 FR(++) n=38 EC145/PLD PLD EC145/PLD PLD Median (months) 14.1 16.9 14.0 16.4 Hazard Ratio (95% CI) 1.099 (0.722, 1.673) 1.420 (0.631, 3.194) 6-month Survival Rate 81% 70% 73% 60% 12-month Survival Rate 62% 63% 64% 53% • ITT OS
Slide 12: 2:1 Randomization Introduced Greater Variability in Control Arm OS Curve
2:1 Randomization Introduced Greater Variability in Control Arm OS Curve Months ITT Patient Population EC145 + PLD (n=100) PLD Alone (n=49) PRECEDENT PLD control survival is more than 4 months longer than historic EC145/PLD Median PLD Median
Slide 13: Imbalance in PFI and Post-Trial Platinum Therapy May Have Confounded OS Results
Imbalance in PFI and Post-Trial Platinum Therapy May Have Confounded OS Results % of Patients ITT FR(++) EC145/PLD PLD EC145/PLD PLD > 3 months platinum free interval* 56% 76% 57% 73% Received post-study chemotherapy 70% 71% 65% 80% Platinum 18% 33% 17% 27% Topotecan 34% 31% 44% 33% Gemcitabine 27%
Slide 14: Exploratory Analysis OS
OS Exploratory Analysis Overall Survival Hazard Ratio Population (events by arm) N (1) Unadjusted Analysis Adjusted Analysis (2) ITT ( events: 70/32) 1.099 0.928 FR(++) (events: 18/10) 1.420 0.495 1. EC20 scan assessment available for 94 of 149 patients. 2. Results from Cox proportional hazards mode
Slide 15: Overall Survival Conclusions
Overall Survival Conclusions • Underpowered, particularly in the control arm (49 patients) • Control arm curve median is significantly longer than in historical PLD trials • Imbalance in platinum free interval and post platinum therapy may have impacted results • Results inconclusive
Slide 16: Implications for Phase 3 Study
Implications for Phase 3 Study • Validation of EC20 allows us to focus on FR(++) population • Higher confidence that phase 2 results repeated in phase 3 study • Primary endpoint of phase 3 on blinded investigator reads • Include platinum free interval in stratification • 1:1 Randomization FR(++) Pop
Slide 17: Questions & Answers
Questions & Answers